Carregant...
Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes
BACKGROUND: Glycated hemoglobin (HbA1c) is accepted as the most reliable marker for assessing chronic glycemia. The present study aimed to investigate glycemic control in cardiovascular outcome trials (CVOTs) performed by pharmaceutical sponsors, at the request of the United States Food and Drug Adm...
Guardat en:
| Publicat a: | J Pharm Policy Pract |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6859615/ https://ncbi.nlm.nih.gov/pubmed/31832207 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40545-019-0193-y |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|